Literature DB >> 4700485

Responsiveness of growth hormone-deficient children to human growth hormone. Effect of replacement therapy for one year.

D Rudman, J H Patterson, D L Gibbas.   

Abstract

Previous studies have shown that growth hormone (GH)-deficient children are more responsive to exogenous human growth hormone (HGH) than non-GH-deficient children. In six GH-deficient children, velocity of linear growth was less than 2.5 cm/yr. By the metabolic balance study technique, anabolic responses (increments in elemental balances) were measured to a 7 day course of 0.0532 U HGH/kg body weight (BW)(3/4) per day (dose B) and to 0.168 U/kg BW(3/4) per day (dose C). They were then treated for 1 yr with HGH at a dose intermediate between B and C. Velocity of linear growth accelerated to 15-25 cm/yr for the first 4-7 mo, then declined to 0-8 cm/yr. At 12 mo, responsiveness to doses B and C was measured again; the responses were only 20-60% as great as before treatment. After 3 mo without HGH treatment, responsiveness to the anabolic effects of doses B and C returned to the magnitudes observed before treatment. A low titer of plasma antibodies to HGH was detected in two of the six children at the end of the year's treatment; these titers showed little change after 3 mo without HGH. Thus the hyperresponsiveness of GH-deficient subjects to exogenous HGH, compared to non-GH-deficient individuals, declines during long-term HGH treatment and is restored by 3 mo interruption of treatment. These changes in peripheral responsiveness may be related to the decline in velocity of linear growth which occurs after 4-7 mo of continuous treatment. When HGH was withdrawn after 12 mo, all six patients exhibited negative balances of N, P, Na, and K and loss of BW. Ratios of elemental balances showed about half the weight loss to represent protoplasm, and about half extracellular fluid. These observations indicate a role of GH in the continuing regulation of nitrogen and mineral metabolism in addition to its function as a growth-promoting hormone.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4700485      PMCID: PMC302365          DOI: 10.1172/JCI107276

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  ANTIBODIES TO HUMAN GROWTH HORMONE (HGH) IN HUMAN SUBJECTS TREATED WITH HGH.

Authors:  J ROTH; S M GLICK; R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  THE EFFECT OF HUMAN GROWTH HORMONE IN HYPOPITUITARY DWARFISM.

Authors:  A PRADER; R ILLIG; J SZEKY; H WAGNER
Journal:  Arch Dis Child       Date:  1964-12       Impact factor: 3.791

3.  Effects of growth hormone on protein and carbohydrate metabolism.

Authors:  J A RUSSELL
Journal:  Am J Clin Nutr       Date:  1957 Jul-Aug       Impact factor: 7.045

4.  Growth hormone. 2. Clinical use of human growth hormone.

Authors:  M S RABEN
Journal:  N Engl J Med       Date:  1962-01-11       Impact factor: 91.245

5.  Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy.

Authors:  D Rudman; S B Chyatte; J H Patterson; G G Gerron; I O'Beirne; J Barlow; A Jordan; J S Shavin
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

6.  Effects of human growth hormone in man.

Authors:  P H HENNEMAN; A P FORBES; M MOLDAWER; E F DEMPSEY; E L CARROLL
Journal:  J Clin Invest       Date:  1960-08       Impact factor: 14.808

7.  Diurnal variation in the responsiveness of human subjects to human growth hormone.

Authors:  D Rudman; D Friedes; J H Patterson; D L Gibbas
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

8.  Growth hormone antibodies in patients treated with different preparations of human growth hormone (HGH).

Authors:  R Illig
Journal:  J Clin Endocrinol Metab       Date:  1970-12       Impact factor: 5.958

9.  TREATMENT OF SHORT STATURE IN CHILDREN AND ADOLESCENTS WITH HUMAN PITUITARY GROWTH HORMONE (RABEN).

Authors:  L F SOYKA; A ZISKIND; J D CRAWFORD
Journal:  N Engl J Med       Date:  1964-10-08       Impact factor: 91.245

10.  Observations on the responsiveness of human subjects to human growth hormone. Effects of endogenous growth hormone deficiency and myotinic dystrophy.

Authors:  D Rudman; S B Chyatte; J H Patterson; G G Gerron; I O'Beirne; J Barlow; P Ahmann; A Jordan; R C Mosteller
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

View more
  2 in total

1.  Reflecting on 80 years of excellence.

Authors:  Ushma Savla
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

2.  Insulin secretion in growth hormone-deficient children and the effect of the sulfonylurea drug glibenclamide on linear growth.

Authors:  E Heinze; W Beischer; W M Teller
Journal:  Eur J Pediatr       Date:  1978-05-22       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.